120 related articles for article (PubMed ID: 37190881)
1. Fully order restricted multi-arm multi-stage clinical trial design.
Kanapka L; Ivanova A
Stat Med; 2023 Jul; 42(17):3050-3066. PubMed ID: 37190881
[TBL] [Abstract][Full Text] [Related]
2. A Bayesian multi-arm multi-stage clinical trial design incorporating information about treatment ordering.
Serra A; Mozgunov P; Jaki T
Stat Med; 2023 Jul; 42(16):2841-2854. PubMed ID: 37158302
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. An order restricted multi-arm multi-stage clinical trial design.
Serra A; Mozgunov P; Jaki T
Stat Med; 2022 Apr; 41(9):1613-1626. PubMed ID: 35048391
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
6. Type I error rates of multi-arm multi-stage clinical trials: strong control and impact of intermediate outcomes.
Bratton DJ; Parmar MK; Phillips PP; Choodari-Oskooei B
Trials; 2016 Jul; 17(1):309. PubMed ID: 27369182
[TBL] [Abstract][Full Text] [Related]
7. Designs for adding a treatment arm to an ongoing clinical trial.
Bennett M; Mander AP
Trials; 2020 Mar; 21(1):251. PubMed ID: 32143729
[TBL] [Abstract][Full Text] [Related]
8. Adding new experimental arms to randomised clinical trials: Impact on error rates.
Choodari-Oskooei B; Bratton DJ; Gannon MR; Meade AM; Sydes MR; Parmar MK
Clin Trials; 2020 Jun; 17(3):273-284. PubMed ID: 32063029
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncology.
Jacob L; Uvarova M; Boulet S; Begaj I; Chevret S
BMC Med Res Methodol; 2016 Jun; 16():67. PubMed ID: 27250349
[TBL] [Abstract][Full Text] [Related]
10. A multi-stage drop-the-losers design for multi-arm clinical trials.
Wason J; Stallard N; Bowden J; Jennison C
Stat Methods Med Res; 2017 Feb; 26(1):508-524. PubMed ID: 25228636
[TBL] [Abstract][Full Text] [Related]
11. Sample size calculation for multi-arm parallel design with restricted mean survival time.
Chen Y; Lam KF; Xu J
Stat Methods Med Res; 2024 Jan; 33(1):130-147. PubMed ID: 38093411
[TBL] [Abstract][Full Text] [Related]
12. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
13. Some recommendations for multi-arm multi-stage trials.
Wason J; Magirr D; Law M; Jaki T
Stat Methods Med Res; 2016 Apr; 25(2):716-27. PubMed ID: 23242385
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
[TBL] [Abstract][Full Text] [Related]
15. Designing multi-arm multi-stage clinical trials using a risk-benefit criterion for treatment selection.
Jaki T; Hampson LV
Stat Med; 2016 Feb; 35(4):522-33. PubMed ID: 26456537
[TBL] [Abstract][Full Text] [Related]
16. Controlling type I error rates in multi-arm clinical trials: A case for the false discovery rate.
Wason JMS; Robertson DS
Pharm Stat; 2021 Jan; 20(1):109-116. PubMed ID: 32790026
[TBL] [Abstract][Full Text] [Related]
17. Controlling the family-wise error rate in multi-arm, multi-stage trials.
Crouch LA; Dodd LE; Proschan MA
Clin Trials; 2017 Jun; 14(3):237-245. PubMed ID: 28545335
[TBL] [Abstract][Full Text] [Related]
18. Planning multi-arm screening studies within the context of a drug development program.
Wason JM; Jaki T; Stallard N
Stat Med; 2013 Sep; 32(20):3424-35. PubMed ID: 23529936
[TBL] [Abstract][Full Text] [Related]
19. A simulation study of outcome adaptive randomization in multi-arm clinical trials.
Wathen JK; Thall PF
Clin Trials; 2017 Oct; 14(5):432-440. PubMed ID: 28982263
[TBL] [Abstract][Full Text] [Related]
20. An optimised multi-arm multi-stage clinical trial design for unknown variance.
Grayling MJ; Wason JMS; Mander AP
Contemp Clin Trials; 2018 Apr; 67():116-120. PubMed ID: 29474933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
